




RealRate

HEALTH SERVICES 2020

Lisata Therapeutics INC Rank 41 of 69





RealRate

HEALTH SERVICES 2020

Lisata Therapeutics INC Rank 41 of 69



The relative strengths and weaknesses of Lisata Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lisata Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Lisata Therapeutics INC is the variable Net Income, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 143%, being 19% points below the market average of 162%.

Input Variable	Value in 1000 USD
Assets, Current	25,972
Assets, Non-Current	1,081
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	9,295
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	5,976
Long Term Liabilities	624
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	25
Other Expenses	0
Other Liabilities	0
Other Net Income	740
Other Revenues	0
Property Plant and Equipment	100
Research And Development Expense	10,797
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	27,153
Liabilities	6,600
Expenses	20,092
Revenues	0
Stockholders Equity	20,553
Net Income	-19,352
Comprehensive Net Income	-19,327
BaseVar	27,305
ECR before LimitedLiability	62%
Economic Capital Ratio	143%